Treatment of Malignant Pleural Mesothelioma with Cisplatin, Mitomycin C and Alpha Interferon
作者:
Sualp Tansan,
Salïh Emri,
Toros Selçuk,
Yener Koç,
Paul Hesketh,
Tim Heeren,
Ronald P. McCaffrey,
Yusuf İzzettin Barış,
期刊:
Oncology
(Karger Available online 1994)
卷期:
Volume 51,
issue 4
页码: 348-351
ISSN:0030-2414
年代: 1994
DOI:10.1159/000227363
出版商: S. Karger AG
关键词: Mesothelioma;Chemotherapy;α-Interferon
数据来源: Karger
摘要:
From October 1990 to September 1991, 20 consecutive patients with histologically proven malignant pleural mesothelioma (MPM), secondary to environmental exposure to asbestos or erionite, were treated with cisplatin, mitomycin C and alpha interferon (cisplatin 50 mg/m2 i.v. on day 1 of a 21-day cycle; mitomycin C 10 mg/m2 i.v. day 1 of cycles 1, 3 and 5; alpha-2b-interferon 10 × 106 units i.m., 4 h prior to cisplatin and 10 × 106 units i.v. immediately prior to cisplatin day 1 of each cycle). Eighty-two treatment cycles were administered to 19 evaluable patients. Two patients attained a partial response. Eleven patients had stable disease and 6 had disease progression. Toxicities included interferon-related fever and flu-like symptoms, and vomiting. Actuarial median survival was 15 months. Three patients are alive at 20+, 21+ and 27+ months. We conclude that while the addition of alpha interferon to cisplatin and mitomycin C did not result in an objective response higher than previously reported with the cytotoxic agents alone, the trend towards an improvement in median survival as compared to a well-matched historical group suggests some benefit from the inclusion of interfero
点击下载:
PDF
(1647KB)
返 回